Trials / Completed
CompletedNCT00309062
Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis
A Multicentre Randomised Placebo-controlled Double-blind Clinical Trial for Evaluation of Safety and Efficacy of Immunotherapy With an Aluminium Hydroxide-adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen, Bet v 1
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Allergopharma GmbH & Co. KG · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
Safety and efficacy of recombinant birch pollen allergen in the treatment of allergic rhinoconjunctivitis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Recombinant birch pollen |
Timeline
- Start date
- 2003-12-01
- Primary completion
- 2006-06-01
- Completion
- 2009-06-01
- First posted
- 2006-03-31
- Last updated
- 2013-03-11
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00309062. Inclusion in this directory is not an endorsement.